ID: hyp-sda-2026-04-01-001-4
Hypothesis
TYROBP-SYK Pathway Enhancement
Selective TYROBP stabilization and SYK pathway activation to maintain neuroprotective signaling downstream of TREM2.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["TREM2 Receptor Activation<br/>Amyloid and Lipid Ligand Binding"]
B["TYROBP DAP12 Adaptor Protein<br/>Plasma Membrane TREM2 Anchoring"]
C["ITAM Phosphorylation<br/>SYK Kinase Recruitment"]
D["SYK Downstream Signaling<br/>PLCgamma PI3K Akt Cascade"]
E["Microglial Survival Phagocytosis<br/>Lipid Metabolism Program"]
F["AD ALS Pathology Reduces TYROBP<br/>Signaling Scaffold Destabilized"]
G["Selective TYROBP Stabilization<br/>Protein Stability Enhancement Strategy"]
H["SYK Activity Maintained<br/>Neuroprotective Signaling Restored"]
A --> B
B --> C
C --> D
D --> E
F -.->|"disrupts"| B
G --> B
G --> H
H --> E
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Supports
Microglial TYROBP/DAP12 in Alzheimer's disease: Transduction of physiological and pathological signals across TREM2.
Supports
The SYK tyrosine kinase: a crucial player in diverse biological functions.
Supports
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ['TYROBP'
No curated PDB or AlphaFold mapping for ['TYROBP' yet. Search RCSB →
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ['TYROBP', 'SYK'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%💾 Resource Usage
LLM Tokens
14,692
$0.0882
Total Cost
$0.0882
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary murine microglia are treated with a TYROBP stabilizer (e.g., small molecule or viral TYROBP overexpression) for 48 hours, THEN phospho-SYK (p-SYK) levels will increase by at least 50% compa | Increased SYK phosphorylation (p-SYK/total SYK ratio) as measured by western blot or phospho-flow cytometry, along with upregulated expression of downstream neu | — no observation — | pending | 0.75 |
| IF 5xFAD amyloid mice (3 months old) receive intracranial AAV-mediated TYROBP overexpression in hippocampus for 8 weeks, THEN amyloid plaque-associated microglia will show enhanced SYK activation and | Increased p-SYK intensity in Iba1+ plaque-associated microglia (measured by immunohistochemistry quantification) and decreased pro-inflammatory gene expression | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF primary murine microglia are treated with a TYROBP stabilizer (e.g., small molecule or viral TYROBP overexpression) for 48 hours, THEN phospho-SYK (p-SYK) levels will increase by at least 50% compared to vehicle-treated controls, using cultured primary microglia isolated from adult C57BL/6 mice.
Predicted outcome: Increased SYK phosphorylation (p-SYK/total SYK ratio) as measured by western blot or phospho-flow cytometry, along with upregulated expression of down
Falsification: No significant increase in p-SYK levels (<20% change) or downstream neuroprotective marker expression despite confirmed TYROBP stabilization would DISPROVE the hypothesis that TYROBP stabilization act
pendingconf 72%
IF 5xFAD amyloid mice (3 months old) receive intracranial AAV-mediated TYROBP overexpression in hippocampus for 8 weeks, THEN amyloid plaque-associated microglia will show enhanced SYK activation and reduced neurotoxic marker expression (iNOS, IL-1β) compared to AAV-GFP controls, using the 5xFAD mou
Predicted outcome: Increased p-SYK intensity in Iba1+ plaque-associated microglia (measured by immunohistochemistry quantification) and decreased pro-inflammatory gene e
Falsification: No increase in microglial p-SYK at amyloid plaques OR no reduction in neurotoxic markers despite confirmed TYROBP overexpression would DISPROVE the hypothesis that TYROBP-SYK enhancement maintains neu
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.